Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of March 2026 (Report No. 7)
Date of Filing: March 25, 2026
The filing reports the issuance of a press release regarding positive 5-year top-line results from the ICESECRET kidney cancer cryoablation study.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical study results and does not contain financial statements or operational financial data.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The primary update is the announcement of clinical efficacy data:
- Study: ICESECRET Kidney Cancer Cryoablation Study.
- Result: 5-year top-line results reported.
- Recurrence-Free Rates: 89.4% and 83.9%.
Guidance, Outlook, and Risks
Management Commentary: The CEO, Eyal Shamir, signed the report, highlighting the positive clinical outcomes of the ICESECRET study as a key milestone for the company's cryoablation technology.
Risks and Contingencies: The filing text does not explicitly detail new risks, contingencies, or unusual items beyond the standard incorporation by reference into existing registration statements.
Guidance: No specific financial guidance or future outlook numbers are provided in this document.
Investor Verification Checklist
- Verify the full details of the ICESECRET study methodology and patient cohort in the attached press release (Exhibit 99.1).
- Confirm the specific definitions for the reported 89.4% and 83.9% recurrence-free rates (e.g., local vs. distant recurrence).
- Review the Company's most recent Form 20-F or quarterly reports for current financial status, as this 6-K contains no financial data.
- Assess the potential impact of these clinical results on regulatory approval timelines and commercialization strategy.